They reported that it does not matter whether BRAF mutation (m-BRAF) or BRAF amplification (a-BRAF) is considered: both activate the RAS/RAF pathway but have different effects on the survival rate of patients with GBM. The gene discussed is BRAF; the disease is glioblastoma.